PRN1371 is a potent and selective small molecule inhibitor primarily investigated for its role in cancer therapy. It functions by targeting specific signaling pathways involved in tumor growth and survival, particularly those associated with receptor tyrosine kinases. Its main application lies in oncology research, where it demonstrates strong anti-tumor activity in preclinical models, especially in cancers driven by aberrant kinase signaling. Due to its high selectivity and efficacy, PRN171 has been explored as a potential therapeutic agent in solid tumors, with a focus on improving treatment outcomes in resistant or advanced cancers. It is also used as a research tool to study kinase inhibition mechanisms and tumor cell response in vitro and in vivo.